Interestingly, targeting Akt2 in microglia with an inhibitor decreased the pro-inflammatory transition in microglial cells and neutrophil activation, indicating a possible novel therapeutic target for early AMD [34]. The gene discussed is AKT2; the disease is age-related macular degeneration.